Monitor the annual meeting outcome for approval of the authorized share increase and equity plan amendment, which could signal future dilution. No immediate trading action warranted; the filing is routine.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 29 $5.17entry
- T+1 · 7mo ago +3.09%α +2.07% · $5.33
- T+5 · 7mo ago +9.48%α +6.37% · $5.66
- T+20 · 6mo ago −8.12%α −14.17% · $4.75
- T+60 · 4mo ago −22.24%α −26.35% · $4.02
Price Chart
How similar events traded
Executive Summary
Protara Therapeutics filed definitive additional proxy materials for its 2026 Annual Meeting of Stockholders to be held on June 12, 2026. The board recommends voting FOR all director nominees, ratification of Ernst & Young as auditor, advisory approval of executive compensation, the equity incentive plan amendment, the increase in authorized shares from 100M to 200M, and officer exculpation, with a 1-year frequency for say-on-pay votes. This is a routine proxy solicitation with no contested matters or material financial disclosures.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for June 12, 2026 at 12:00 PM ET
- Proposals include election of three Class III directors, ratification of Ernst & Young, advisory say-on-pay, frequency vote, amendment to 2024 Equity Incentive Plan, increase in authorized shares from 100M to 200M, and officer exculpation amendment
- Board recommends FOR all proposals and 1 YEAR for say-on-pay frequency
- No financial data or material business changes disclosed in the filing
Financial Impact
No material financial impact disclosed; routine governance proposals only.
Risk Factors
- Potential dilution if authorized share increase and equity plan amendments are approved and utilized
- No operational or financial updates provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-048556 |
| Document: 0001213900-26-048556-index-headers.html | 0001213900-26-048556 |
| Document: 0001213900-26-048556-index.html | 0001213900-26-048556 |
| Document: 0001213900-26-048556.txt | 0001213900-26-048556 |
Track record
13 reports on TARA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers